Eterna Historical Cash Flow
| ERNA Stock | USD 0.29 0.03 9.38% |
Analysis of Eterna Therapeutics cash flow over time is an excellent tool to project Eterna Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as End Period Cash Flow of 12.3 M or Stock Based Compensation of 1.2 M as it is a great indicator of Eterna Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Eterna Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Eterna Therapeutics is a good buy for the upcoming year.
Eterna |
About Eterna Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Eterna balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Eterna's non-liquid assets can be easily converted into cash.
Eterna Therapeutics Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Free Cash Flow
The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Most accounts from Eterna Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Eterna Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eterna Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Eterna Stock refer to our How to Trade Eterna Stock guide.At present, Eterna Therapeutics' Total Cash From Financing Activities is projected to increase significantly based on the last few years of reporting. The current year's End Period Cash Flow is expected to grow to about 12.3 M, whereas Change In Cash is forecasted to decline to (4.1 M).
Eterna Therapeutics cash flow statement Correlations
Click cells to compare fundamentals
Eterna Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Eterna Therapeutics cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 673K | (3.5M) | 15.4M | (1.4M) | (3.9M) | (4.1M) | |
| Other Cashflows From Financing Activities | (37K) | (39K) | 10K | (109K) | (251K) | (238.5K) | |
| Capital Expenditures | 1.1M | 39K | 154K | 297K | 19K | 18.1K | |
| Total Cash From Financing Activities | (1.1M) | 4.7M | 61.6M | 19.6M | 16.6M | 17.4M | |
| End Period Cash Flow | 3.3M | 1.6M | 17.0M | 15.5M | 11.7M | 12.3M | |
| Stock Based Compensation | 206K | 91K | 5.2M | 2.9M | 1.2M | 1.2M | |
| Free Cash Flow | 1.7M | (8.1M) | (23.6M) | (21.3M) | (20.4M) | (21.4M) | |
| Depreciation | 3.2M | 98K | 459K | 497K | 1.1M | 1.1M | |
| Other Non Cash Items | 7.2M | 19.2M | 86.1M | (3.5M) | 1.0M | 961.4K | |
| Total Cash From Operating Activities | 2.7M | (8.1M) | (23.5M) | (21.0M) | (20.4M) | (21.4M) | |
| Net Income | (2.0M) | (7.3M) | (122.3M) | (24.6M) | (21.7M) | (22.8M) | |
| Change In Working Capital | (37K) | (999K) | (2.4M) | 3.7M | (2.1M) | (2.0M) | |
| Begin Period Cash Flow | 2.6M | 5.1M | 1.6M | 17.0M | 15.5M | 16.3M | |
| Change To Account Receivables | (248K) | 1.7M | (659K) | (262K) | 527K | 553.4K | |
| Total Cashflows From Investing Activities | (606.1K) | (39K) | (22.7M) | (47K) | (42.3K) | (44.4K) | |
| Change To Operating Activities | 9.2K | (69K) | (1.1M) | 1.7M | 1.9M | 2.0M | |
| Change To Netincome | 195.0K | 91K | 100.9M | (604K) | (694.6K) | (659.9K) | |
| Change To Liabilities | (1.1M) | (930K) | (485K) | 2.0M | 2.3M | 2.5M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Eterna Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eterna Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eterna Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eterna Therapeutics Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eterna Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Eterna Stock refer to our How to Trade Eterna Stock guide.You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eterna Therapeutics. If investors know Eterna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eterna Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.31) | Revenue Per Share 0.03 | Return On Assets (0.29) | Return On Equity (11.54) |
The market value of Eterna Therapeutics is measured differently than its book value, which is the value of Eterna that is recorded on the company's balance sheet. Investors also form their own opinion of Eterna Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Eterna Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eterna Therapeutics' market value can be influenced by many factors that don't directly affect Eterna Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eterna Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eterna Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eterna Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.